PriceTargets.com logo

Hemispherx BioPharma - HEB Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.46 As of 06/7/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for HEB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hemispherx BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HEB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HEB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Hemispherx BioPharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.46.

This chart shows the closing price for HEB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Hemispherx BioPharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/22/2019Maxim GroupDowngradeBuy ➝ Hold
8/21/2019Ascendiant Capital MarketsSet TargetBuy$6.00
8/9/2019Maxim GroupReiterated RatingBuy$8.00
6/14/2019Maxim GroupInitiated CoverageBuy$8.00
5/17/2019Ascendiant Capital MarketsSet TargetBuy$44.00
(Data available from 6/8/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Hemispherx BioPharma logo
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Read More

Today's Range

Now: $0.46
Low: $0.45
High: $0.47

50 Day Range

MA: N/A

52 Week Range

Now: $0.46
Low: $1.69
High: $14.81

Volume

23,713 shs

Average Volume

102,599 shs

Market Capitalization

$1.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hemispherx BioPharma?

The following Wall Street analysts have issued reports on Hemispherx BioPharma in the last twelve months:
View the latest analyst ratings for HEB.

What is the current price target for Hemispherx BioPharma?

0 Wall Street analysts have set twelve-month price targets for Hemispherx BioPharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hemispherx BioPharma in the next year.
View the latest price targets for HEB.

What is the current consensus analyst rating for Hemispherx BioPharma?

Hemispherx BioPharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HEB.

What other companies compete with Hemispherx BioPharma?

Other companies that are similar to Hemispherx BioPharma include RespireRx Pharmaceuticals, Assure, Sunwin Stevia International, Scopus BioPharma and Altamira Therapeutics. Learn More about companies similar to Hemispherx BioPharma.

How do I contact Hemispherx BioPharma's investor relations team?

Hemispherx BioPharma's physical mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company's listed phone number is +1-407-2718516. The official website for Hemispherx BioPharma is www.hemispherx.net. Learn More about contacing Hemispherx BioPharma investor relations.